Cure My Disease

Don't miss your cure!

 Log in / Sign up

Special forces veterans test Psychedelic-Device combo for PTSD and brain injury

NCT ID NCT07717866

Disease control Sponsor: Axial Therapeutic Research Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study looks at whether a combination of ibogaine-magnesium, 5-MeO-DMT, magnetic e-Resonance therapy (MeRT), and physiological supplements can help special operations veterans with PTSD, depression, suicidal thoughts, and cognitive problems from traumatic brain injury. Participants receive these treatments in a specific order and are followed for a year. The goal is to see if this multi-pronged approach improves symptoms and brain function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a combination of ibogaine-magnesium, 5-MeO-DMT, magnetic e-Resonance therapy (MeRT), and physiological supplements
What this could lead to
If successful, this combination approach could offer a new way to reduce PTSD, depression, and cognitive problems in veterans who have not responded to standard treatments.
What could go wrong
This is an early observational study with no control group, so results may be due to placebo or other factors. The treatments also carry risks, including heart issues and psychological distress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

52 people

The number who actually took part.

Started

Aug 2022

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants were obtained from a cohort of treatment-seeking SOF veterans with problems in mental health including PTSD, cognitive symptoms related to traumatic brain injury, depression, and suicidality. Participants were selected and sponsored by SOC-F.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * At least 18 years of age * Sponsored by SOC-F Program Exclusion Criteria (evaluated by SOC-F, not Axial Therapeutic Research): * Diagnosis of Schizophrenia, Bipolar I or II disorder for which patient has been hospitalized or medicated, Depersonalization and/or Derealization Disorder * Cerebellar dysfunction, Epilepsy, Psychosis or acute confusional state, Dementia * Prolonged corrected QT interval (QTc) Interval (450ms in males; 470ms in females) * History of heart failure or hypertrophic heart * Active blood clots (e.g., Pulmonary embolism, Deep vein thrombosis) * Major respiratory conditions (e.g., Emphysema, Cystic fibrosis) * Severe chronic gastrointestinal issues (e.g., bleeding ulcer, leaky gut syndrome) * Within 6 months of surgeries * Abnormal blood test results (e.g., potassium or magnesium outside normal range) * Impaired kidney or liver function * Refusal to taper off of selective serotonin reuptake inhibitor (SSRI) medication

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain injury are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain injury cognitive disorder Cognitive Dysfunction combat disorder Depression major depressive disorder post-traumatic stress disorder Suicidal Ideation traumatic brain injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain injury Cognitive dysfunction Depression - major depressive disorder PTSD, post traumatic stress disorder Suicidal ideation

Contacts and locations

Locations

  • Axial Therapeutic Research

    Northridge, California, 91325, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.